[go: up one dir, main page]

MX2016001165A - Estabilizacion de polipeptidos que contienen fragmentos cristalizables. - Google Patents

Estabilizacion de polipeptidos que contienen fragmentos cristalizables.

Info

Publication number
MX2016001165A
MX2016001165A MX2016001165A MX2016001165A MX2016001165A MX 2016001165 A MX2016001165 A MX 2016001165A MX 2016001165 A MX2016001165 A MX 2016001165A MX 2016001165 A MX2016001165 A MX 2016001165A MX 2016001165 A MX2016001165 A MX 2016001165A
Authority
MX
Mexico
Prior art keywords
polypeptides
stabilization
polypeptides containing
containing crystallizable
crystallizable fragments
Prior art date
Application number
MX2016001165A
Other languages
English (en)
Inventor
Gunasekaran Kannan
Frederick W Jacobsen
Jennifer Lavallee
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2016001165A publication Critical patent/MX2016001165A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)

Abstract

La descripción proporciona polipéptidos que comprenden una región Fc de anticuerpo que tiene una deleción de uno o más residuos de cisteína en la región de bisagra y sustitución con un residuo que contienen sulfhidrilo de uno o más aminoácidos de interfase CH3. También, se proporcionan proteínas de fusión Fc y anticuerpos que contienen los polipéptidos, ácidos nucleicos y vectores que codifican los polipéptidos, junto con células hospederas y métodos para elaborar los polipéptidos.
MX2016001165A 2013-07-31 2014-07-30 Estabilizacion de polipeptidos que contienen fragmentos cristalizables. MX2016001165A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361860800P 2013-07-31 2013-07-31
PCT/US2014/048908 WO2015017548A2 (en) 2013-07-31 2014-07-30 Stabilization of fc-containing polypeptides

Publications (1)

Publication Number Publication Date
MX2016001165A true MX2016001165A (es) 2016-06-29

Family

ID=52432568

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016001165A MX2016001165A (es) 2013-07-31 2014-07-30 Estabilizacion de polipeptidos que contienen fragmentos cristalizables.
MX2022008013A MX2022008013A (es) 2013-07-31 2016-01-27 Estabilizacion de polipeptidos que contienen fragmentos cristalizables.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022008013A MX2022008013A (es) 2013-07-31 2016-01-27 Estabilizacion de polipeptidos que contienen fragmentos cristalizables.

Country Status (15)

Country Link
US (3) US20160193295A1 (es)
EP (1) EP3027647A4 (es)
JP (2) JP2016526909A (es)
KR (3) KR20250152665A (es)
CN (1) CN105658664A (es)
AU (3) AU2014296215A1 (es)
BR (1) BR112016002219A2 (es)
CA (1) CA2919076C (es)
CL (1) CL2016000232A1 (es)
EA (1) EA035319B1 (es)
HK (1) HK1224203A1 (es)
IL (1) IL243690B (es)
MX (2) MX2016001165A (es)
SG (1) SG11201600734YA (es)
WO (1) WO2015017548A2 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013148117A1 (en) 2012-03-27 2013-10-03 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
RU2704285C2 (ru) 2013-01-30 2019-10-25 Нгм Байофармасьютикалз, Инк. Композиции и способы применения для лечения метаболических расстройств
FR3012453B1 (fr) 2013-10-31 2015-11-13 Lab Francais Du Fractionnement Proteine chimerique dans le traitement de l’amylose
TWI710570B (zh) 2014-07-30 2020-11-21 美商Ｎｇｍ生物製藥公司 用於治療代謝異常之組成物及方法
EA036985B1 (ru) 2014-10-31 2021-01-25 НДжМ БИОФАРМАСЬЮТИКАЛЗ, ИНК. Композиции и способы лечения метаболических расстройств
CA2966776C (en) 2014-12-19 2021-05-04 Alkermes, Inc. Single chain fc fusion proteins
IL256989B (en) 2015-08-07 2022-08-01 Alx Oncology Inc Constructs with a sirp-alpha site or a variant thereof
CN109475627B (zh) 2016-05-26 2023-01-06 齐鲁普吉湾生物治疗公司 抗体混合物
CA3026393C (en) 2016-06-22 2023-03-14 Alkermes, Inc. Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties
CA3043630A1 (en) * 2016-12-22 2018-06-28 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
US20190367611A1 (en) * 2017-02-01 2019-12-05 CentryMed Pharmaceutical Inc. Monomeric human igg1 fc and bispecific antibodies
TWI832818B (zh) * 2017-07-07 2024-02-21 南韓商韓美藥品股份有限公司 新穎的治療性酵素融合蛋白及其用途
CN119390821A (zh) 2017-08-15 2025-02-07 伊兰科美国公司 兽药用IgG Fc变体
CN107540748B (zh) * 2017-09-15 2020-07-14 北京伟杰信生物科技有限公司 长效重组猪fsh融合蛋白及其制备方法与应用
EA202091239A1 (ru) * 2017-12-22 2020-09-09 Ханми Фарм. Ко., Лтд. Слитый белок на основе терапевтического фермента, имеющий новую структуру, и его применение
TWI724392B (zh) 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
CN109021109A (zh) * 2018-07-20 2018-12-18 上海交通大学 一种牛源性抗金黄色葡萄球菌融合抗体scFv-Fc及其制备方法
AU2019314999B2 (en) 2018-08-03 2025-12-04 Amgen Inc. Antibody constructs for CLDN18.2 and CD3
KR102148405B1 (ko) * 2018-09-19 2020-08-27 주식회사 바이오앱 돼지의 Fc 단편을 포함하는 재조합 벡터 및 상기 벡터를 이용한 재조합 단백질의 제조 방법
KR102200773B1 (ko) * 2018-09-19 2021-01-12 주식회사 바이오앱 돼지의 Fc 단편과 융합된 항원 및 이를 포함하는 백신 조성물
US10947278B2 (en) * 2018-09-19 2021-03-16 Bioapplications Inc. Recombinant vector comprising porcine FC fragment and preparation method of recombinant protein using thereof
WO2020167957A1 (en) * 2019-02-12 2020-08-20 Board Of Regents, The University Of Texas System High affinity engineered t-cell receptors targeting cmv infected cells
EP3976099A1 (en) 2019-05-31 2022-04-06 ALX Oncology Inc. Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor
MA56120A (fr) 2019-06-07 2022-04-13 Amgen Inc Constructions de liaison bispécifiques
JOP20220068A1 (ar) * 2019-09-18 2023-01-30 Novartis Ag بروتينات اندماج nkg2d واستخداماتها
US11542276B2 (en) 2019-11-25 2023-01-03 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
JP7713447B2 (ja) 2019-11-27 2025-07-25 エーエルエックス オンコロジー インコーポレイテッド がんを治療するための組み合わせ療法
EP4071166A4 (en) * 2019-12-11 2023-07-26 Lg Chem, Ltd. Fusion polypeptide comprising gdf15 and polypeptide region capable of o-glycosylation
WO2021150824A1 (en) 2020-01-22 2021-07-29 Amgen Research (Munich) Gmbh Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
JP7481856B2 (ja) 2020-02-25 2024-05-13 シスメックス株式会社 改変抗体及びその製造方法、並びに抗体の熱安定性を向上させる方法
CN111285936A (zh) * 2020-03-11 2020-06-16 北京双赢科创生物科技有限公司 靶向肿瘤的酸性敏感纳米肽段及其应用
US20230146593A1 (en) 2020-03-12 2023-05-11 Amgen Inc. Method for treatment and prophylaxis of crs in patients comprising a combination of bispecific antibodies binding to cds x cancer cell and tnf alpha or il-6 inhibitor
JP2023527293A (ja) 2020-05-19 2023-06-28 アムジエン・インコーポレーテツド Ｍａｇｅｂ２結合構築物
WO2022032660A1 (zh) * 2020-08-14 2022-02-17 武汉友微生物技术有限公司 新型冠状病毒rbd融合蛋白
JP7627413B2 (ja) * 2020-08-21 2025-02-06 ファチアブジェン インコーポレイテッド ガンマ定常領域（Ｃγ１）とイプシロン定常領域（Ｃε２－４）とが融合された重鎖及び軽鎖の定常領域からなる抗体断片及びその用途
CN114426974B (zh) * 2020-10-29 2023-11-21 洛阳普泰生物技术有限公司 特异性结合非洲猪瘟病毒CD2v蛋白的抗体或抗体片段
MX2023005063A (es) 2020-11-02 2023-05-12 Attralus Inc Proteinas de fusion sap fc y metodos de uso.
PE20231516A1 (es) 2020-11-06 2023-09-28 Amgen Res Munich Gmbh Construcciones polipeptidicas que se unen selectivamente a cldn6 y cd3
WO2022120286A1 (en) * 2020-12-06 2022-06-09 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
CA3216908A1 (en) 2021-05-13 2022-11-17 ALX Oncology Inc. Combination therapies for treating cancer
US20240350588A1 (en) * 2021-08-24 2024-10-24 Sunshine Lake Pharma Co., Ltd. Gdf15 fusion proteins and use thereof
CN116064562A (zh) * 2022-10-28 2023-05-05 江南大学 玉米赤霉烯酮的真核表达单链抗体以及全长抗体的制备方法以及用途
CN116284455B (zh) * 2023-04-17 2024-10-11 北京康乐卫士生物技术股份有限公司 一种带状疱疹病毒疫苗的嵌合抗原及其应用
WO2025036564A1 (de) * 2023-08-17 2025-02-20 Gottfried Wilhelm Leibniz Universität Hannover (Luh) Nukleinsäuresequenz, vektor, screening-verfahren und verfahren zur herstellung von rekombinanten antikörpern
WO2025162458A1 (zh) * 2024-02-04 2025-08-07 南通壹宸生物医药科技有限公司 融合抗体及其制备和应用
CN118344462B (zh) * 2024-06-18 2024-11-08 苏州易合医药有限公司 一种用于肺部给药的索马鲁肽突变体、融合蛋白及相关产品
CN119613573B (zh) * 2025-02-14 2025-05-30 浙江大学 一种CD40L-Fc融合蛋白、基因片段、重组质粒、重组细胞以及制备方法和用途
CN119735654B (zh) * 2025-02-27 2025-07-01 浙江海隆生物科技股份有限公司 一种牛副流感病毒的亚单位hn蛋白制备方法和应用
CN120623322B (zh) * 2025-08-14 2025-12-05 成都蓉生药业有限责任公司 一种人IgG Fc变体、基因片段、表达载体、宿主细胞、IgG抗体及人IgG Fc变体制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7951917B1 (en) * 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US20030207346A1 (en) * 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
JP4213224B2 (ja) * 1997-05-02 2009-01-21 ジェネンテック，インコーポレーテッド ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754209B2 (en) * 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
JP2008511337A (ja) * 2004-09-02 2008-04-17 ジェネンテック・インコーポレーテッド ヘテロ多量体分子
EA016609B1 (ru) * 2005-11-28 2012-06-29 Генмаб А/С Рекомбинантные моновалентные антитела и способы их получения
CA2781539C (en) * 2009-11-23 2021-07-20 Amgen Inc. Monomeric antibody fc
SI2648752T1 (sl) * 2010-12-06 2017-06-30 Seattle Genetics, Inc. Humanizirana protitelesa proti Liv-1 in njihova uporaba za zdravljenje raka

Also Published As

Publication number Publication date
KR20160034404A (ko) 2016-03-29
KR20230141929A (ko) 2023-10-10
EA035319B1 (ru) 2020-05-27
JP2016526909A (ja) 2016-09-08
US20250325631A1 (en) 2025-10-23
WO2015017548A3 (en) 2015-11-05
AU2014296215A1 (en) 2016-02-11
IL243690A0 (en) 2016-04-21
CA2919076A1 (en) 2015-02-05
KR20250152665A (ko) 2025-10-23
AU2022201204B2 (en) 2025-01-02
HK1224203A1 (zh) 2017-08-18
US20190192628A1 (en) 2019-06-27
EA201690299A1 (ru) 2016-11-30
IL243690B (en) 2022-09-01
AU2020200329A1 (en) 2020-02-06
BR112016002219A2 (pt) 2017-09-12
WO2015017548A2 (en) 2015-02-05
CA2919076C (en) 2024-01-30
JP2021019598A (ja) 2021-02-18
AU2022201204A1 (en) 2022-03-17
EP3027647A4 (en) 2017-01-04
MX2022008013A (es) 2022-07-27
EP3027647A2 (en) 2016-06-08
CN105658664A (zh) 2016-06-08
US20160193295A1 (en) 2016-07-07
CL2016000232A1 (es) 2016-09-02
JP7344858B2 (ja) 2023-09-14
SG11201600734YA (en) 2016-02-26

Similar Documents

Publication Publication Date Title
MX2016001165A (es) Estabilizacion de polipeptidos que contienen fragmentos cristalizables.
CO2017005639A2 (es) Anticuerpos anti-miostatina, polipéptidos que contienen regiones fc variantes
MX2023007211A (es) Anticuerpos antimiostatina y metodos de uso.
PH12018501280A1 (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
MX2021013355A (es) Composiciones de proteínas de fusión quiméricas modificadas y métodos de uso de las mismas.
PH12019500782A1 (en) Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments
MX2018012539A (es) Composiciones y métodos de células t receptoras de aloantígeno quimérico.
AR090706A1 (es) Metodo para preparar peptidos tensioactivos
CO2018002450A2 (es) Proteínas de fusión de gitrl y usos de las mismas
CL2019000261A1 (es) Polipéptidos modificados y usos de los mismos.
MX2022000012A (es) Prediccion de epitopos de celulas t utiles para vacunacion.
EA032960B1 (ru) Антитела, содержащие химерные константные домены
MX2017004664A (es) Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria.
PE20170503A1 (es) Proteinas de fusion de interleucina 2/receptor de interleucina-2 alfa y metodos de uso
EA202091166A1 (ru) ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ Fc С ИЗМЕНЕННЫМ ГЛИКОЗИЛИРОВАНИЕМ И СНИЖЕННОЙ ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
CO2022010422A2 (es) Anticuerpo anti antígeno-4 asociado al linfocito t citotóxico (ctla-4) y uso del mismo
UY38542A (es) Neoantígenos próstaticos, vacunas y composiciones farmacéuticas que los contienen
EA201791918A1 (ru) Модификация белков клеток-хозяев
UY36678A (es) Anticuerpos anti-fcrn.
EA201691548A1 (ru) Экспрессирующие конструкции и способы для отбора клеток-хозяев, экспрессирующих полипептиды
PE20151757A1 (es) Anticuerpos anti-cd52
AR105689A1 (es) Proteínas de fusión gitrl y sus usos
AR106774A1 (es) Anticuerpos y fragmentos de anticuerpo para la conjugación sitio-específica
NZ750009A (en) Antibodies comprising chimeric constant domains